Shasun  
Search Go
 
Shasun  
Spacer Spacer
      Home Our Offering Bulk API
Spacer Spacer Spacer
 
» Services & Solutions
» Formulation
» Products
Spacer
» Biotech
» Shasun Infrastructure
» India
» UK
 

Our Offerings

 
 

Bulk API Offering*

 
S. No. PRODUCTS CAS # REGULATORY FILING-DMF COS
US Europe
Other
 

Pain management & Musculoskeletal

         
1 Ibuprofen (SN,S-250,S-380,S-500,SHD) 15687-27-1
  Ibuprofen DC grades (DC-60, 90, 85) 15687-27-1      
  S+ Ibuprofen 51146-56-6  
  Ibuprofen Lysinate 57469-76-8    
  Ibuprofen Sodium (Powder & Crystal) 31121-93-4
 
2 Carisoprodol 78-44-4      
 

Hyperphosphataemia

         
3 Sevelamer Hydrochloride 52757-95-6      
4 Sevelamer Carbonate 845273-93-0      
 

Central Nervous system

         
5 Methohexital 18652-93-2  
6 Meprobamate 57-53-4      
7 Gabapentin 60142-96-3    
8 Olanzapine Form-I 132539-06-1    
 

Cardiovascular

         
9 Isradipine 75695-93-1      
10 Quinapril Hydrochloride 82586-55-8      
11 Colesevelam Hydrochloride 182815-44-7      
 

Anti-Infective

         
12 Cycloserine 68-41-7      
13 Chlorphenesin 104-29-0        
 

Gastrointestinal

         
14 Ranitidine Base 66357-35-5  
  Ranitidine Form-I 66357-59-3
  Ranitidine Form-II 66357-59-3
15 Nizatidine 76963-41-2
 

Other Prodcts

         
16 Sulphazine (n-1 Sumatriptan) 81880-96-8      
17 Diphenhydramine citrate 88637-37-0        
   
  *We respects patent laws and conventions of pharmaceuticals as applicable in different countries. However we cannot determine the patent status for each of the products in individual countries. It is the Client's responsibility to ensure that the Products are not sold either directly or indirectly in any jurisdiction where the sale of such products would infringe third party rights including but not limited to patent infringements.
   
 
S. No. PIPELINE PRODUCTS CAS #
1 Ketoprofen 56105-81-8
2 Florfenicol 73231-34-2
3 Tenofovir Disoproxil Fumarate 202138-50-9
4 Lacidipine 103890-78-4
   
  Shasun has more products in the pipeline at various stages of development.
Please contact us for more details
   
 
   
Our Offering Investor Relations News & Media Center Careers